Drugs / Pneumovax
Pneumovax
also known as
Pneumovax 23 · 23-valent pneumococcal vaccine · Pneumo23 · Pneumococcal polysaccharide vaccine · PPS23
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00589394 | Jul 2007 → Dec 2008 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT03460730 | Nov 2004 → Jul 2006 | streptococcal pneumonia | KEMRI-Wellcome Trust Collaborative Research Program | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00137605 | Sep 2004 → Oct 2007 | pneumococcal infection | CIHR Canadian HIV Trials Network | Completed | No outcome recorded |
| Phase 43 trials · 1 missed | ||||||
| Phase 4 | NCT00152802 | Jan 2005 → Jan 2009 | disease related to solid organ transplantation | University Health Network, Toronto | Unknown | Missed primary |
| Phase 4 | NCT00304382 | Jan 2003 → Sep 2006 | pneumococcal infection, pneumonia | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 4 | NCT00143780 | May 2002 → Jul 2006 | bone marrow disorder | University Health Network, Toronto | Completed | No outcome recorded |
| Phase not applicable4 trials · 1 missed | ||||||
| — | NCT02707692 | Aug 2016 → Apr 2020 | AIDS | University of California, San Diego | Completed | Missed primary |
| — | NCT02126384 | Nov 2014 → Apr 2016 | pneumococcal infection | French National Institute of Health and Medical Research | Completed | No outcome recorded |
| — | NCT01307449 | Apr 2014 → Jul 2017 | pneumococcal infection | Emory University | Completed | No outcome recorded |
| — | NCT00829595 | May 2005 → Dec 2007 | Crohn disease, ulcerative colitis | Cedars-Sinai Medical Center | Completed | No outcome recorded |
| Comparator or background therapy12 trials | ||||||
| Phase 1 | NCT06474377 Comparator | Jun → Aug 2024 | pneumococcal infection | Sinovac Life Sciences Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT07543198 Comparator | Jun 2025 → Feb 2026 | pneumococcal infection | Sinovac Life Sciences Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT03873727 Background | Aug 2019 → May 2022 | — | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 2 | NCT01414504 Comparator | Dec 2009 → Sep 2011 | — | William Pomat | Completed | No outcome recorded |
| Phase 3 | NCT04214444 Background | Jul 2020 → May 2024 | diffuse large B-cell lymphoma, pneumococcal infection | University Hospital, Tours | Completed | No outcome recorded |
| Phase 3 | NCT01892618 Comparator | Aug 2013 → Dec 2015 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Karolinska University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00457977 Comparator | Mar 2007 → May 2011 | chronic obstructive pulmonary disease | University of Minnesota | Completed | No outcome recorded |
| Phase 4 | NCT03095326 Background | Sep 2013 → Feb 2014 | pneumococcal infection, thalassemia | Faculty of Medicine, University of Indonesia | Completed | No outcome recorded |
| Phase 4 | NCT01947010 Comparator | Jul 2013 → Aug 2014 | Crohn disease | Statens Serum Institut | Completed | No outcome recorded |
| Phase 4 | NCT01781871 Comparator | Jan 2013 → Oct 2017 | — | Helsinki University Central Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00836641 Comparator | Oct 2006 → Oct 2008 | asthma | Johann Wolfgang Goethe University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00023504 Comparator | Jun 2002 → May 2017 | immunodeficiency disease | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 22 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pneumovax | “a 13-valent conjugate vaccine (Prevenar®) and a 23-valent polysaccharide vaccine (Pneumovax®)” NCT04214444 ↗21“0.5mL Pneumovax at 9 months and 0.1mL Pneumovax at 3-5 yrs” NCT01414504 ↗ “PPV pneumococcal vaccine (Pneumovax®)” NCT03095326 ↗ |
| Known as | 23-valent pneumococcal vaccine | “About 20% of patients with pneumococcal pneumonia in our previous study had been vaccinated with the only vaccine currently in use for adults, namely 23-valent pneumococcal...” NCT00304382 ↗ |
| Known as | Pneumo23 | “receive either Pneumovax (or Pneumo23 according to standard use at site) or heptavalent pneumococcal conjugate vaccine (Prevnar)” NCT00137605 ↗ |
| Known as | Pneumococcal polysaccharide vaccine | “Pneumococcal polysaccharide vaccine(Pneumovax®) is suboptimal in this patient group.” NCT01781871 ↗ |
| Known as | Pneumovax 23 | “single 0.5 ml sub-cutaneous dose of 23 valent pneumococcal polysaccharide vaccine (Pneumovax 23) to compare the dynamics” NCT03460730 ↗1“Participants first received a 0.5 mL injection of Pneumococcal vaccine (Pneumovax-23®).” NCT02707692 ↗ |
| Known as | PPS23 | “Prevenar13 (PCV13) and Pneumovax (PPS23)” NCT03873727 ↗ |
| Modality | Vaccine | “using Pneumococcal vaccine immunization” NCT00023504 ↗ |
| Route | Other | “Injection” NCT00457977 ↗ |